Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem
PubMed
37414534
DOI
10.1136/jnnp-2023-331499
PII: jnnp-2023-331499
Knihovny.cz E-zdroje
- Klíčová slova
- MULTIPLE SCLEROSIS, STATISTICS,
- MeSH
- dimethyl fumarát terapeutické užití MeSH
- fingolimod hydrochlorid terapeutické užití MeSH
- glatiramer acetát terapeutické užití MeSH
- imunosupresiva terapeutické užití MeSH
- interferon beta terapeutické užití MeSH
- lidé MeSH
- natalizumab terapeutické užití MeSH
- recidiva MeSH
- relabující-remitující roztroušená skleróza * farmakoterapie MeSH
- roztroušená skleróza * farmakoterapie MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- dimethyl fumarát MeSH
- fingolimod hydrochlorid MeSH
- glatiramer acetát MeSH
- imunosupresiva MeSH
- interferon beta MeSH
- natalizumab MeSH
- teriflunomide MeSH Prohlížeč
BACKGROUND: Simultaneous comparisons of multiple disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) over an extended follow-up are lacking. Here we emulate a randomised trial simultaneously comparing the effectiveness of six commonly used therapies over 5 years. METHODS: Data from 74 centres in 35 countries were sourced from MSBase. For each patient, the first eligible intervention was analysed, censoring at change/discontinuation of treatment. The compared interventions included natalizumab, fingolimod, dimethyl fumarate, teriflunomide, interferon beta, glatiramer acetate and no treatment. Marginal structural Cox models (MSMs) were used to estimate the average treatment effects (ATEs) and the average treatment effects among the treated (ATT), rebalancing the compared groups at 6-monthly intervals on age, sex, birth-year, pregnancy status, treatment, relapses, disease duration, disability and disease course. The outcomes analysed were incidence of relapses, 12-month confirmed disability worsening and improvement. RESULTS: 23 236 eligible patients were diagnosed with RRMS or clinically isolated syndrome. Compared with glatiramer acetate (reference), several therapies showed a superior ATE in reducing relapses: natalizumab (HR=0.44, 95% CI=0.40 to 0.50), fingolimod (HR=0.60, 95% CI=0.54 to 0.66) and dimethyl fumarate (HR=0.78, 95% CI=0.66 to 0.92). Further, natalizumab (HR=0.43, 95% CI=0.32 to 0.56) showed a superior ATE in reducing disability worsening and in disability improvement (HR=1.32, 95% CI=1.08 to 1.60). The pairwise ATT comparisons also showed superior effects of natalizumab followed by fingolimod on relapses and disability. CONCLUSIONS: The effectiveness of natalizumab and fingolimod in active RRMS is superior to dimethyl fumarate, teriflunomide, glatiramer acetate and interferon beta. This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously.
CHUM MS Center Montreal Quebec Canada
CISSS de Chaudiere Appalaches Levis Quebec Canada
CORe Department of Medicine The University of Melbourne Melbourne Victoria Australia
Department of Medicine and Surgery University of Parma Parma Italy
Department of Medicine Sultan Qaboos University Hospital Seeb Oman
Department of Neurology Alfred Hospital Melbourne Victoria Australia
Department of Neurology American University of Beirut Beirut Lebanon
Department of Neurology ASL3 Genovese Genova Italy
Department of Neurology Center of Clinical Neuroscience Charles University Praha Czech Republic
Department of Neurology Centro Hospitalar de São João Porto Portugal
Department of Neurology Faculty of Medicine Hacettepe University Ankara Turkey
Department of Neurology Galdakao Usansolo Hospital Galdakao Spain
Department of Neurology Hospital General de Alicante Alicante Spain
Department of Neurology Isfahan University of Medical Sciences Isfahan Iran
Department of Neurology John Hunter Hospital Newcastle New South Wales Australia
Department of Neurology King Fahad Specialist Hospital Dammam Khobar Saudi Arabia
Department of Neurology Koc Universitesi Istanbul Turkey
Department of Neurology Razi University Hospital Tunis Tunisia
Department of Neurology St Vincent's University Hospital Dublin Ireland
Department of Neurology University of Debrecen Debrecen Hungary
Department of Neurology University of Tunis El Manar Tunis Tunisia
Department of Neurology Zuyderland Medical Centre Sittard Geleen Sittard Geleen The Netherlands
Department of Neuroscience Azienda Ospedaliero Universitaria di Modena Modena Italy
Department of Neuroscience Central Clinical School Monash University Melbourne Victoria Australia
Dipartimento di Scienze Biomediche e Neuromotorie Università di Bologna Bologna Italy
Division of Neurology Department of Medicine Amiri Hospital Kuwait City Kuwait
Dokuz Eylul University İzmir Turkey
Flinders University Adelaide South Australia Australia
General University Hospital Prague Praha Czech Republic
Groene Hart Ziekenhuis Gouda The Netherlands
Johns Hopkins University Bloomberg School of Public Health Baltimore Maryland USA
Koc University Research Center for Translational Medicine Istanbul Turkey
KTU Medical Faculty Farabi Hospital Trabzon Turkey
Liverpool Hospital Sydney New South Wales Australia
Nemocnice Jihlava Jihlava Czech Republic
Neuro Rive Sud Greenfield Park Quebec Canada
Neurology Hospital Universitario Reina Sofia Cordoba Spain
Neurology Hospital Universitario Virgen Macarena Sevilla Spain
Ospedali Riuniti di Salerno Salerno Italy
Royal Victoria Hospital Belfast UK
School for Mental Health and Neuroscience Maastricht University Maastricht The Netherlands
School of Medicine Ondokuz Mayis Universitesi Samsun Turkey
South and East Belfast Health and Social Services Trust Belfast UK
Sultan Qaboos University Muscat Oman
Universitair Ziekenhuis Gent Gent Belgium
Universite de Montreal Montreal Quebec Canada
University Hospital Geelong Geelong Victoria Australia
University of Basel Basel Switzerland
University of Newcastle Hunter Medical Research Institute Newcastle New South Wales Australia
UOC Neurologia Azienda Sanitaria Unica Regionale Marche AV3 Macerata Italy
UQCCR The University of Queensland Brisbane Queensland Australia
Citace poskytuje Crossref.org